Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

August 11, 2017: By Jon Swedien

ZeissCarl Zeiss Meditec’s revenues for Q3-2016/17 were €277.2 million ($325.8 million, as of Aug. 10, 2017), the German company reported Aug. 7.

That marks a 7.5 percent increase over the company’s Q3-2015/16 revenues.

Zeiss’ revenues during the first nine months of its 2016/17 fiscal year totaled €864.7 million ($1 billion, as of Aug. 10, 2017), marking an 8.3 percent (7.2 percent, cc) increase over the same three quarters from the previous year, Zeiss said.

Ophthalmology sales lead the way for much of the growth, the company said.

Zeiss’ ophthalmic devices strategic business unit recorded €639.9 million ($752 million, as of Aug. 10, 2017), in revenues during the first nine month of Zeiss’ current fiscal year, the company said.

That marks a 9.2 percent (82 percent, cc) increase over the first nine months of the company’s previous fiscal year, Zeiss said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022